Reynoso Jamie L. sold $11K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 2,384 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.68 on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 9, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The transaction is primarily a disclosure of insider activity. Without new company fundamentals, it is more likely to influence short-term sentiment than to change valuation drivers.

02

Market read

Traders may note the insider sale for sentiment, but it is unlikely to be a standalone catalyst.

03

What to watch

The filing does not disclose any new company-specific catalyst (earnings, guidance, trials, contracts), so traders should avoid over-weighting it versus upcoming fundamentals.

Relevance 2/10Novelty 3/10Timing: Filed after-hours on 2026-07-09, reflecting a 2026-07-08 sale.

Background

This is an SEC Form 4 reporting an officer’s open-market sale of CLOV shares, with a stated pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Jamie L. Reynoso sold 2,384 shares on 2026-07-08 at $4.6800, totaling $11,157.12, under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying new operational or guidance information.

Market effects

Minimal read-through to the Medicare Advantage/healthcare services sector because this is a small, planned insider transaction.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Clover Health Investments, Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • Reynoso Jamie L.

    CEO, Medicare Advantage, who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.